Startup Funding

Menu
Subscribe
Search

•
Fundraising, Investing

Related Guides

    Trending

    The most popular articles on Startup Funding in the past day.

    The Growth Story Framework: What Top VCs Look for in Follow-On Rounds

    June 14, 2026

    7 min read The Growth Story Framework: What Top VCs Look for in Follow-On Rounds Early-stage investors often focus on vision, team, and market potential. But when it comes to follow-on rounds—Series A, B, and beyond—the evaluation criteria shifts dramatically. Later-stage investors are not buying possibility; they’re underwriting performance, scalability, and durability. Understanding how growth-stage VCs evaluate companies doesn’t just help founders prepare for their next round—it helps angels and seed investors make smarter initial bets and support portfolio companies more effectively. It also sharpens exit strategy thinking from day one. Here’s the framework top VCs use when deciding whether to lean in—or walk away. 1. Narrative Consistency: Is the Growth Story Coherent? Growth-stage investors look for a clear, consistent narrative from inception to scale. The story must connect early traction to a larger strategic opportunity: Why this market? Why this model? Why now? If the company’s direction has pivoted multiple times without a compelling throughline, it raises questions about strategic clarity. The best companies demonstrate evolution—not randomness. Every stage builds logically on the last. Takeaway: Early investors should help founders craft a scalable narrative from day one. A company’s “Series A story” is often seeded in its pre-seed pitch. 2. Revenue Quality: Not Just Growth, but Durable Growth At the seed stage, 3x–5x growth can compensate for messy fundamentals. In follow-on rounds, that’s no longer enough. Later-stage VCs dissect revenue composition with precision: Customer concentration Retention cohorts Net revenue retention (NRR) Expansion revenue Gross margins Sales efficiency They want to know: Is this growth repeatable? Predictable? Profitable at scale? A company growing 100% year-over-year with strong retention and improving unit economics is fundamentally different from one buying growth through heavy discounting and churn. Takeaway: Angels should pay attention to revenue quality early. Supporting founders in building strong reporting habits and disciplined GTM processes pays off later. 3. Execution Depth: Can This Team Operate at Scale? Early-stage investing is often a bet on raw talent and founder grit. Later-stage investing evaluates operational maturity. Growth investors assess: Leadership bench strength Functional expertise (sales, finance, operations) Hiring velocity and retention Board governance KPI visibility and forecasting discipline A strong founder is essential—but insufficient. VCs want to see a management team that can run a multi-million (or multi-hundred-million) revenue engine. Takeaway: Smart early investors encourage founders to upgrade talent proactively—not reactively. Scaling companies require scaling leadership. 4. Capital Efficiency: How Much Fuel to Create the Next Milestone? Follow-on investors aren’t just asking, How big can this get? They’re asking, How efficiently can it get there? Burn multiple, CAC payback, and runway discipline matter. Even in bullish markets, growth-stage VCs prefer companies that demonstrate thoughtful capital allocation. In tighter markets, this becomes non-negotiable. Companies that can articulate exactly how $20M translates into defined ARR, margin expansion, or market share gains signal strategic maturity. Takeaway: Early investors should help founders treat capital as strategic leverage, not validation. Efficient companies have more financing options—and stronger negotiating power. 5. Exit Optionality: Is There a Clear Strategic Path? By the time a company reaches later-stage funding, investors are modeling outcomes. Who are the logical acquirers? What valuation benchmarks are realistic? Is there a credible IPO path? How defensible is the competitive moat? Follow-on investors want to see multiple exit pathways, not a single aspirational scenario. They’re underwriting return profiles based on risk-adjusted probability. For angels, this perspective is critical. A company that looks exciting at seed may struggle to attract growth capital if it lacks a clear path to liquidity. Takeaway: Exit strategy thinking shouldn’t start at Series C. It should inform market selection and business model design from the beginning. Why This Framework Matters for Early Investors Too often, early investors think in isolation: Is this a good seed deal? The better question is: Will this be a good Series A or B company? When angels understand how growth-stage VCs evaluate opportunities, they can: Select startups more likely to secure follow-on capital Coach founders toward scalable metrics Reduce dilution risk Increase probability of meaningful exits In other words, they invest with the end in mind. Building With the Future Round in Mind The most successful companies don’t “prepare for a Series A” at the last minute. They build in alignment with what growth capital demands from the start. As an investor or founder, ask yourself: Are we building durable growth—or temporary momentum? Are our metrics institutional-grade? Is our narrative scaling with our traction? Are we designing for exit optionality? These are not late-stage questions. They are foundational ones. Final Thought The Growth Story Framework is more than a fundraising checklist—it’s a strategic lens. Whether you’re writing your first check or preparing your next round, understanding how top VCs think will elevate your decisions. If you found this helpful, subscribe for deeper insights on startup finance, growth strategy, and investor intelligence. And if you’re supporting portfolio companies today, share this framework with them—it may shape their next round more than you think.

    Why Early AI Revenue Hides More Risk Than It Removes

    April 12, 2026

    5 min read Why Early AI Revenue Hides More Risk Than It Removes In today’s AI market, early revenue is often treated as proof of momentum. A signed contract, a recognizable customer logo, or a growing usage chart can quickly create the impression that risk is coming off the table. For many investors, that feels like validation. But in AI, early revenue often does not reduce risk. It often conceals it. At TEN Capital, we believe this distinction matters most for family offices and long-term investors. In emerging categories, revenue can create a sense of comfort before a business has earned durability. And when that happens, investors are not underwriting certainty. They are underwriting a story. The real question is not whether an AI company has revenue. The real question is whether that revenue reveals a durable business model. or delays the discovery of its weaknesses. Revenue Is Not the Same as Validation In traditional software, early revenue has often been a meaningful signal. It can suggest product-market fit, pricing power, and disciplined execution. Investors have been trained to see revenue as evidence that a company is moving in the right direction. AI requires a more careful lens. Many early AI buyers are not making long-term purchasing decisions. They are testing capabilities, funding internal learning, and exploring what the technology can do. In other words, they are often buying experimentation rather than embedding a permanent solution into the business. That is why early AI revenue can be misleading. It may look like commercial traction, while in reality, it reflects temporary curiosity, discretionary budget allocation, or non-repeatable deployments. For investors, especially those focused on downside protection, this is where diligence has to deepen rather than relax. The Pilot Trap That Inflates Confidence One of the most common distortions in AI investing is the way early revenue is categorized and interpreted. What looks like recurring revenue is often one of three things: pilot revenue dressed up as ARR, consulting work reported as product revenue, or subsidized experimentation that has not yet faced real commercial pressure. These revenue streams can look strong in a deck or spreadsheet, but they tend to behave poorly under stress. They churn faster, stall during procurement, get repriced under scrutiny, or disappear entirely when budgets tighten. The danger is not simply that these revenues are fragile. The deeper problem is that founders and investors often value them as if they are durable. Once that happens, the business gets framed as de-risked before the hard questions have been answered. The Cost Curve Is Where the Risk Actually Lives For AI companies, revenue alone tells only a small part of the story. The more important issue is whether the economics improve or deteriorate as usage grows. Early AI revenue often arrives before true unit economics are visible. Compute costs may still be partially subsidized. Engineering labor may be buried inside implementation. Inference expenses may rise faster than pricing can support. Gross margin assumptions may look promising in theory while remaining unproven in practice. This is why early traction can be deceptive. Revenue growth can delay the moment when investors are forced to confront whether the business actually scales in an economically sound way. A company can appear to be gaining momentum even as its underlying cost structure grows more fragile with each additional customer. Why Early Revenue Can Weaken Diligence In many cases, revenue does not sharpen investor discipline. It softens it. Without revenue, investors tend to ask harder questions immediately. What happens when usage expands? What happens when the underlying models commoditize? What happens when pricing compresses? What happens if the customer internalizes the capability instead of continuing to pay for it? Once revenue exists, those questions often lose urgency. The company starts to look validated. The conversation shifts from structural risk to growth narrative. And that is often the point where the most important diligence gets deferred. In AI, revenue should not be treated as an excuse to stop probing. It should be treated as a prompt to understand exactly what is being monetized, and how durable that monetization really is. Why Family Offices Need a Different Lens This matters to all investors, but especially to family offices. Traditional venture funds can tolerate weaker businesses because portfolio construction allows a few exceptional winners to drive returns. High churn, unclear retention, and low margins can be survivable at the fund level if one outlier eventually breaks through. Family offices usually play a different game. They are often more focused on capital preservation, risk-adjusted outcomes, and long-term compounding. They feel opportunity cost more directly. They absorb underperformance differently. And they generally have less tolerance for narratives that take years to resolve into economic truth. That makes fragile AI revenue particularly dangerous. When early revenue delays the discovery of weakness, family offices are often the first to feel the cost of that mistake. What Actually De-Risks an AI Business At TEN Capital, we believe the strongest de-risking signals in AI are structural, not cosmetic. Headline ARR matters far less than the durability beneath it. Investors should spend more time on questions like: Can margins remain resilient as the company scales?How deeply does the customer depend on the product?Are switching costs real or merely assumed?Is the cost structure transparent?Can the founder clearly explain downside scenarios and uncomfortable numbers? These are the markers of a company that understands its own business model. Revenue without this level of clarity is often just decoration. Revenue with this level of clarity is much closer to evidence. A Better Question Than “How Much ARR?” There is a more useful question investors should be asking: What happens to this revenue when pricing power weakens? That question cuts through hype quickly. It forces a conversation about margin sensitivity, customer behavior, the risk of commoditization, and retention durability. It reveals whether the company has built real leverage — or is simply benefiting from temporary market enthusiasm. In our view, that single question filters out a meaningful share of fragile

    The Real Map Is a Revenue-Risk Kill Sequence

    March 8, 2026

    5 min read The Real Map Is a Revenue-Risk Kill Sequence Deeptech founders love milestone maps. They outline the science, engineering steps, validation protocols, and integration milestones with pride. And at the seed stage, that’s fine. Seed investors fund the possibility. Series A–C investors, however, fund inevitability. And inevitability is not created by clearing technical hurdles. It is created by eliminating the commercial risks that prevent a technology from becoming a business. This is the misunderstanding at the heart of most deeptech storytelling: Founders organize the story around technical progress. Investors organize the story around revenue-risk collapse. This is why so many deeptech pitches fall flat, not because the technology isn’t compelling, but because the narrative answers the wrong questions. Series A–C investors are not buying the sophistication of your engineering timeline. They are buying the sequence that makes commercial risk impossible. Let’s unpack how to transform a science-first milestone map into a VC-grade revenue-risk kill sequence that accelerates decision-making, shortens diligence, and gives investors confidence that you understand the physics of commercialization. The Dangerous Assumption: “Technical Progress = Commercial Progress.” Deeptech founders often assume: Once the algorithm is working → customers will adopt Once the reactor is efficient → utilities will sign Once the sensor is accurate → OEMs will integrate Once the material performs → manufacturers will switch This assumption is not naïve; it’s human. You believe in your work because it is technically elegant. But investors are not evaluating your elegance; they are evaluating your commercial inevitability. Here’s the uncomfortable truth: Commercial adoption rarely tracks the order of your technical milestones. It tracks the order of: Who feels pain first Who has the budget now Who can integrate the soonest Who has the most to lose by waiting If your milestones don’t prioritize these, your round will feel “too early,” even if the science is world-class. Series A–C Investors Evaluate One Thing: “How Fast Do You Remove the Kill Shots?” A “kill shot” is a risk that, if not addressed early, will kill the entire business. Examples of kill shots: The buyer who should adopt first doesn’t have a budget path Integration into an OEM cycle requires 18 months; you didn’t budget Manufacturing scale requires capex that your Series B cannot support Regulatory timelines extend your cash runway by 2× Switching costs are higher than you estimated The quickest way to lose a Series A or B investor is to walk through dozens of technical milestones while leaving kill shots untouched. So the narrative must flip: Not “Here’s what we’ll build.” But “Here’s how we will eliminate the risks that could prevent revenue.” That’s the revenue-risk kill sequence. Framework #1 — The Revenue-Risk Kill Sequence™ Series A–C investors make decisions around five commercial risk categories. Your milestone plan must neutralize them in this order: 1. Market Pain Risk Is the problem strong enough that someone urgently wants it solved? Your milestone: Evidence of acute pain in the earliest adopter segment. 2. Integration Risk How difficult is it to slot your solution into existing workflows or infrastructure? Your milestone: A successful pilot inside the workflow of a real buyer. 3. Economic Risk Can the buyer justify the switch economically? Your milestone: LTV/CAC, ROI, or cost-avoidance math validated by the customer. 4. Timeline Risk Does the buyer have a path to adoption within your funding horizon? Your milestone: A procurement calendar aligned to your cash runway. 5. Scale Risk Can you rapidly meet demand without blowing up costs? Your milestone: Proof of scalable manufacturing, deployment, or integration. If your technical milestones don’t de-risk these five, your A–C rounds will feel like science fundraising, not company building. Framework #2 — Milestone-to-Money Mapping Grid Here’s how investors think: A milestone is meaningful only if it changes the probability or timing of revenue. Try mapping each technical milestone against this grid: Technical Milestone Does It De-Risk Revenue? Does It Accelerate Revenue? VC Interpretation Achieve X% efficiency No No “Cool science, doesn’t change the business.” Complete integration pilot Yes Yes “This is real progress. Shortens time to cash.” File a new patent No No “Defensive but not commercial.” Validate customer ROI Yes Yes “This moves the valuation needle.” Demonstrate scalable production Yes Yes “This makes Series B inevitable.” If a milestone doesn’t shift the probability or timing of revenue, it doesn’t belong in the story. Framework #3 — The Sequence of Commercial Inevitability Investors ask: “If we fund you today, what must happen in the next 18–24 months to make you unfundable only by idiots?” A deeptech company becomes commercially inevitable when: A customer segment feels acute pain Integration is proven and repeatable The economics beat the status quo Procurement cycles are aligned to your runway Scale is de-risked enough for a growth investor This sequence—not your technical timeline—is the backbone of your Series A–C narrative. Heuristic #1 — “Milestones Are a Story, Not a Schedule” A founder’s mistake: “I’ll just walk them through the timeline.” An investor’s reality: “I need to understand the logic of the sequence.” Investors evaluate: Priority logic Dependencies Cost of delay Risk of wrong order Whether milestones ladder to revenue A strong narrative doesn’t say what you’re doing. It explains why you’re doing it in that specific order. Heuristic #2 — “Hit the Risk That Most Scares the Next Round” Series A founders often derisk the wrong things. Series B VCs care about: Customer adoption Unit economics Repeatability Deployment friction If your milestones don’t de-risk these, your Series B round becomes a science project rather than a scaling round. Heuristic #3 — “Remove the Hardest Commercial Risk First” The founder instinct: “Let’s start with what’s easiest and build momentum.” The investor instinct: “Show me you can kill the hardest risk early.” If the hardest bottleneck is: Customer adoption → run a pilot Integration → build the integration Economics → validate ROI Hardware scale → prove manufacturability Regulatory → engage early Hard-first is the path to investor confidence. Case Studies: Pattern Recognition Across Deeptech Robotics Technical milestone: Improve

    Site Map

    Scroll to Top